Clinical Trial

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-06
notable Trial sites reduced: 17 -> 11 locations 2026-08-06
critical Primary endpoint(s) modified 2026-07-21
Trial Details
NCT Number NCT07021066
Lead Sponsor SystImmune Inc.
Conditions Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer, Other Solid Tumors
Enrollment 160 participants
Start Date 2025-07-30
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-05